Expand PTGX Menu
PTGX MENU

PTGX Latest Press Releases

-- April 16, 2024 --

Turnstone Biologics Appoints William Waddill to its Board of Directors Globe Newswire 9:00 AM

-- March 26, 2024 --

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data ACCESSWIRE 7:03 AM

-- March 18, 2024 --

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda ACCESSWIRE 7:02 AM

-- March 11, 2024 --

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year ACCESSWIRE 7:11 AM

-- March 6, 2024 --

Protagonist Therapeutics to Participate in Upcoming Investor Conferences ACCESSWIRE 4:06 PM

-- February 27, 2024 --

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update ACCESSWIRE 4:07 PM

-- February 21, 2024 --

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera ACCESSWIRE 5:01 PM

-- February 20, 2024 --

Protagonist Therapeutics Reports Granting of Inducement Awards ACCESSWIRE 4:05 PM

-- February 7, 2024 --

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study ACCESSWIRE 5:01 PM

-- January 31, 2024 --

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset ACCESSWIRE 4:07 PM

-- January 29, 2024 --

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 ACCESSWIRE 7:41 AM

-- January 3, 2024 --

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference ACCESSWIRE 7:31 AM

-- December 13, 2023 --

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis ACCESSWIRE 7:30 AM